Catalent, Novo Holdings

Novo Holdings closes $16.5 billion buyout of contract manufacturer Catalent
Novo Holdings, the controlling shareholder of Novo Nordisk, on Wednesday sealed its $16.5 billion deal for Catalent, as the Danish drugmaker looks to boost supplies of its widely popular weight-loss drug Wegovy.
Novo Holdings says its acquisition of Catalent is complete.
Indications are that Novo will be investing in both the plant and the community,” an Indiana University professor said.
Novo Holdings Completes Acquisition of Catalent
Catalent, Inc. ("Catalent"), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences investment firm,
Novo Holdings completes $16.5 billion takeover of Catalent
Novo Holdings has completed its $16.5 billion acquisition of Catalent, the contract drug manufacturer said on Wednesday, days after the companies disclosed that all regulatory conditions to close the deal were fulfilled.
Novo Holdings set to close $16.5B Catalent buy in 'coming days' after deal clears antitrust hurdles
After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to unwrap its $16.5 billion present just in time for the holidays.
Novo Holdings’ purchase of Catalent set to close after regulators’ green light
The $16.5 billion take-private deal can now be completed, and along with it Novo Nordisk’s related acquisition of three Catalent drug manufacturing plants.
Novo Holdings completes purchase of Catalent
Novo Holdings said that it completed it's $16.5 billion acquisition of Catalent Inc. (NYSE:CTLT). Shortly following the completion of the deal, Novo Nordisk A/S (NVO)  will acquire from Novo Holdings Catalent’s three fill-finish sites located in Anagni,
pharmaphorum22h
Novo Holdings leads $100m round for novel painkiller biotech
The Series C – which was led by Novo Nordisk's parent company Novo Holdings – follows a $15 million second round for ...
FierceBiotech11h
Novo Holdings leads SiteOne's $100M series C for non-opioid pain treatments
SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target ...
Business Insider11h
Novo Holdings Acquires Catalent In $16.5 Bln Cash Deal
(RTTNews) - Wednesday, Novo Holdings A/S completed the acquisition of Catalent, Inc. (CTLT), a global contract development and manufacturing organization, in an all-cash transaction worth ...
STAT2d
Pharmalittle: We’re reading about Novo Holdings proceeding with Catalent deal, Sanofi threatened with sanctions, and more
Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...
MM&M2d
Novo Holdings’ $16.5B deal for Catalent clears last regulatory hurdle
Novo Holdings is on track to acquire Catalent, a global contract development and manufacturing organization, in a $16.5 ...
Novo Completes $16.5 Billion Acquisition of Catalent
Novo Holdings A/S said Monday that it has completed its $16.5 billion all-cash acquisition of Catalent ( CTLT, Financials ).
Barron's on MSN2d
Novo’s New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way.
The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...